Welcome to Industrysourcing.com!

logoTille
中文 中文

Login/Register

WeChat

For more information, follow us on WeChat

Connect

For more information, contact us on WeChat

Email

You can contact us info@ringiertrade.com

Phone

Contact Us

86-21 6289-5533 x 269

Suggestions or Comments

86-20 2885 5256

Top

BSD showcases MicroThermX at CIRSE

Source:BSD Medical Corporation Release Date:2013-10-11 193
Medical Equipment
Physician interest in the microwave ablation system exceeds expectations at world's largest interventional radiology conference

SALT LAKE CITY – BSD Medical Corporation (NASDAQ: BSDM) reported the successful promotion of the MicroThermX? Microwave Ablation System at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference in Barcelona, Spain. CIRSE is the world's largest and most prestigious conference in the field of minimally invasive image-guided therapies.

Hundreds of physicians attended the MicroThermX symposium, including key physician opinion leaders throughout Europe. Terumo Europe NV (Terumo), a wholly owned subsidiary of Tokyo-based Terumo Corporation, used CIRSE as the main launching pad to showcase BSD's MicroThermX as an integral part of its branded Interventional Oncology Solutions (IOS).

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. It is the first of its kind that allows delivery of higher power levels using a single generator and utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide a wide range of uniform zones of ablation

“We see tremendous opportunity for fast adoption in Europe for our MicroThermX Microwave Ablation System because the structure of the healthcare systems in the area is focused on cost-effective solutions and faster adoption of new superior technology,” said Harold Wolcott, BSD president and CEO. “The physician response and interest in the MicroThermX far exceeded our expectations. We are very pleased with our relationship with Terumo.”

The U.S. Food and Drug Administration (FDA) has granted BSD a 510(k) clearance to market the MicroThermX for ablation of soft tissue. The company has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets.Nike
You May Like